Shareholders in this diagnostics company have witnessed their dividend grow by 340% over the past decade, and that could be just the tip of the iceberg.
Gene sequencing stock Illumina has exploded onto the scene with huge gains for investors, but could the best be yet to come for this exciting company?
PacBio, the post-hype sleeper of genomics.
The market for lab equipment is improving in Europe and the U.S., boosting results for Mettler Toledo.
Diagnostics leader Thermo-Fisher (TMO) could soon make a huge splash in genomics, but it's got plenty of other irons in the fire as well.
The media swarmed over Illumina's announcement of a system capable of sequencing a human genome for $1,000 in the near future, but when will the company and Thermo Fisher Scientific break that barrier on a routine basis?
After a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?
Unlocking the "human code" makes possible all manner of changes we might have never considered before. Are we ready for what that might mean?
Teva Pharmaceutical, AMAG Pharmaceuticals, AstraZeneca, and Nektar Therapeutics could loom large in health-care headlines this morning. Here’s why.
The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.